Obinutuzumab
Mature B-Cell Malignancies
BeOne Medicinesmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Mature B-Cell Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zanubrutinib BeOne Medicines | Phase 1/2 | B |
Copad St. Jude Children's Research Hospital | Phase 2/3 | B |
Autologous Anti-Cd19Car-4-1Bb-Cd3Zeta-Egfrt-Expressing T Lymphocytes Fred Hutchinson Cancer Center | Phase 1/2 | CCC |
Sonrotoclax BeOne Medicines | Phase 1 | CC |
Pirtobrutinib Ou Bai, MD/PHD | D | |
Sgr-1505 Schrödinger, Inc. | Phase 1 | NR |
Same molecule, other indications
Obinutuzumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →